PREDICT-HD Huntington Disease Study

The purpose of this project is to make clinical measurements from the PREDICT-HD consortium available through the dbGaP mechanism. The phenotype data will first be converted into a community open standard and subsequently exported to dbGaP for archival and open access distribution of the results of the studies. This will permit members of the scientific community to utilize a permanent resource for investigating the interactions of phenotypes upon an international cohort of early Huntington Disease. In version 2 cut of the data we provided HD CAG repeat lengths for both alleles as well as enrollment age of all participants. We have also generated unique identifiers prospectively compatible with the larger initiative GWAS in Huntington's Disease project (also on DbGaP). As such, the version 1 cut of the data was mainly proof of concept and should be deprecated. Going forward, all updates will add-on to version 2 cut of the data. In version 3 cut of the data, we provided baseline or the first usable MRI T1-weighted imaging analysis subcortical and cortical segmentations and cortical parcellations based on a customized Freesurfer 5.2 pipeline developed at The University of Iowa. The customizations to the standard pipeline were mainly to improve bias field correction and image normalization such that segmentation of gray, white, internal csf, dura and surface CSF are optimized for the Freesurfer pipeline. There are 1111 subjects with results in this data release. In version 4 cut of the data, we provided all longitudinal clinical measurements for all subjects (total of 1476) assessmented or enrolled through the end of 2013. Additionally, we are providing measurements on 39 baseline FDG PET images spatially normalized by SPM5 into MNI space, relative regional metabolic values computed in 120 volumes of interest (VOI) defined in the Automated Anatomical Labeling (AAL) Atlas (Tzourio-Mazoyer et al. 2002), and global metabolic values calculated by SPM standard mean voxel value (within per image fullmean/8 mask). This project is a funded ancillary study of PREDICT-HD. In version 5 cut of the data, we provided the first of many forthcoming results from ancilliary studies of PREDICT-HD. In this data cut, we provide individual subject results derived from structural MRI data. The earliest MRI session for each subject was used. The results summarized represent source based morphometry loading coefficients for 23 components (see: "Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome", Ciarochi et al., 2016, Front Neurol. 2016; 7: 147, Published online 2016 Sep 21. doi: 10.3389/fneur.2016.00147]. In this version 6 cut of the data, we provide a full set of derived data, more than 10,000 raw MRI images, and ancillary study data sets. For sample information please link to: PREDICT-HD Biospecimen Resources ]]>
Medical History/Demographics (DEMO)Modified Unified Huntington's Disease Rating Scale '99 (UHDRS)Modified UHDRS Part III - ParticipantModified UHDRS Part III - CompanionCognitive Assessment Summary Sheet - Visit 1Section V Psychiatric AssessmentsSection VII UHDRSMODEL PARTICIPANT INFORMED CONSENTBRAINS AutoWorkup Output DescriptionsINCLUSION: The participant completed predictive testing, and CAG is known. The participant is 18 years of age or older at the Screening/Baseline Visit (enrollment). The participant has a support person that will accompany them to all visits. The participant is willing and able to comply with study procedures and give written informed consent. The participant's primary language is consistent with the PREDICT site staff. We have German and Spanish sites whose native language was not English and whose data was obtained in their native languages. All assessment forms were translated and back-translated and all data were checked for language variations in an item-by-item evaluation. No differences were found but we typically covary/control for "site" in many analyses where we are concerned about differences that may have been undetected. 33 Worldwide sites provide the situation where unknown cultural/geographic differences may impact findings. EXCLUSION: The participant has been previously diagnosed with manifest HD. The participant is currently or has in the past 6 months been on antipsychotic medications. This includes typical neuroleptics such as haloperidol, as well as atypical neuroleptics (e.g. Risperidone, clozapine, quetiapine and olanzapine). The participant uses prochlorperazine metoclopramide, promethazine, or Inapsine more than three times/month. The participant exhibits or reports clinical evidence of an unstable medical or psychiatric illness. The participant has a history of alcohol or drug abuse within the past year. The participant has a history of or has a current diagnosis of CNS disorder, including developmental, acquired and/or degenerative syndromes/diseases. The participant has been diagnosed with mental retardation. The participant was always in Special Education for reading or math. Specifically, Special Education relating to learning problems not only behavioral problems. The participant has a history of significant head trauma that required hospitalization. The participant has metallic implants (pacemaker, defibrillator, vagal nerve stimulator, aneurysm clips, metal shrapnel). ]]>
The PREDICT-HD study is a 32-site observational study of persons who have the gene expansion for Huntington Disease (HD), but do not have symptoms of disease warranting a diagnosis. In this regard, the PREDICT-HD study cohort and database have become international resources and offer an unprecedented opportunity to further examine early HD. The goals of the PREDICT-HD study involve laying the groundwork for the initiation of neuroprotective therapy in order to delay or conceivably prevent the onset of disease. The specific aims were designed to 1) improve prediction of disease diagnosis in healthy individuals using longitudinal measures of plasma, imaging, cognitive performances, motor ratings and psychiatric measures; 2) identify markers of disease progression prior to the clinical diagnosis and to characterize their natural history; and 3) improve the validity and reliability of disease measures upon which the power and sensitivity of multi-site trials and studies depend. Given the worldwide distinctiveness of the study and its importance to the advancement of knowledge in HD and other brain diseases, the improved availability and the dissemination of its data is an important emphasis. This project proposes to create an extended electronic data capture and data sharing infrastructure to expand data acquisition and distribution procedures that are expected to improve quality control and data usability. The primary aims of the chosen projects are to 1) provide better user experience for participants and clinicians, and 2) streamline data collection, digital curation, and distribution procedures for researchers external to the core PREDICT-HD project. With future versions of this database, we plan to integrate existing clinical trials management software with medical imaging data repositories.]]>